aTyr Pharma Shares Drop 80% After Lung Disease Drug Fails in Phase 3 Trial
aTyr Pharma's experimental drug efzofitimod failed to meet its primary goal in a late-stage trial for pulmonary sarcoidosis, causing its shares to plummet over 80% to a record low, though the company sees potential benefits and plans to discuss next steps with the FDA.